A meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19
| Autor: | Fang Cheng, Hai yin Jiang, Li ya Pan, Ying feng Lu, Wen Wu Zhang, Xue Zhang, Sha Sha Hu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Microbiology (medical) medicine.medical_specialty Deep vein Pneumonia Viral 030106 microbiology Article lcsh:Infectious and parasitic diseases Betacoronavirus 03 medical and health sciences Antithrombotic 0302 clinical medicine Internal medicine Humans Medicine lcsh:RC109-216 030212 general & internal medicine Pandemics Coagulation SARS-CoV-2 Heparin business.industry Incidence Incidence (epidemiology) Anticoagulants COVID-19 Venous Thromboembolism General Medicine medicine.disease Thrombosis Confidence interval Pulmonary embolism Clinical trial Infectious Diseases medicine.anatomical_structure Meta-analysis Coronavirus Infections business |
| Zdroj: | International Journal of Infectious Diseases, Vol 100, Iss, Pp 34-41 (2020) International Journal of Infectious Diseases |
| ISSN: | 1201-9712 |
| DOI: | 10.1016/j.ijid.2020.08.023 |
| Popis: | Highlights • The incidence of VTE among hospitalised COVID-19 patients was high, particular among patients in ICU. • Anticoagulation was not associated with an increased risk of mortality in hospitalised COVID-19 patients. • Clinical trials are urgently needed to evaluate the roles of prophylactic and therapeutic anticoagulation in COVID-19. Background The incidence of venous thromboembolic events (VTE) in patients with COVID-19 is generally high but varies markedly. However, the relationship between anticoagulation and mortality in patients with COVID-19 is still unclear. Methods We performed a systematic review and meta-analysis to determine the incidence of VTE and evaluate the role of anticoagulation in patients with COVID-19. Random effects models were used to determine overall pooled estimates and 95% confidence intervals (CIs). Results After a database search, 25 observational studies (20 on VTE incidence and 5 on the relationship between anticoagulation and mortality) were included. The pooled incidence rates of VTE, pulmonary embolism (PE), and deep vein thrombosis (DVT) in hospitalised COVID-19 patients were 21% (95% CI 15–27%), 15% (95% CI 10–20%), and 27% (95% CI 19–36%), respectively. A meta-analysis of five studies found that anticoagulation was not associated with an increased risk of mortality in hospitalised COVID-19 patients (RR = 0.86, 95% CI, 0.69–1.09, P = 0.218; I2 = 47.4%). Conclusions In conclusion, the incidence of VTE among hospitalised COVID-19 patients was high. Clinical trials are urgently needed to evaluate the roles of prophylactic and therapeutic anticoagulation in COVID-19. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|